These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

171 related items for PubMed ID: 17139582

  • 1. [Development of body weight during antidiabetic treatment].
    Hamann A.
    Dtsch Med Wochenschr; 2006 Dec; 131 Suppl 8():S255-8. PubMed ID: 17139582
    [Abstract] [Full Text] [Related]

  • 2. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study.
    Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Gravina A, Mereu R, Palumbo I, D'Angelo A, Cicero AF.
    Metabolism; 2009 Aug; 58(8):1059-66. PubMed ID: 19394976
    [Abstract] [Full Text] [Related]

  • 3. Management of type 2 diabetes mellitus with special reference to metformin therapy.
    Campbell IW.
    Diabete Metab; 1991 May; 17(1 Pt 2):191-6. PubMed ID: 1936475
    [Abstract] [Full Text] [Related]

  • 4. Worry vs. knowledge about treatment-associated hypoglycaemia and weight gain in type 2 diabetic patients on metformin and/or sulphonylurea.
    Lund A, Knop FK.
    Curr Med Res Opin; 2012 May; 28(5):731-6. PubMed ID: 22462528
    [Abstract] [Full Text] [Related]

  • 5. Weight gain during insulin therapy in patients with type 2 diabetes mellitus.
    Heller S.
    Diabetes Res Clin Pract; 2004 Sep; 65 Suppl 1():S23-7. PubMed ID: 15315867
    [Abstract] [Full Text] [Related]

  • 6. [Oral antidiabetic therapy].
    Schneider S, Pazdzierny G, Klein HH.
    Dtsch Med Wochenschr; 2006 Dec; 131 Suppl 8():S264-7. PubMed ID: 17139584
    [Abstract] [Full Text] [Related]

  • 7. Metformin causes reduction of food intake and body weight gain and improvement of glucose intolerance in combination with dipeptidyl peptidase IV inhibitor in Zucker fa/fa rats.
    Yasuda N, Inoue T, Nagakura T, Yamazaki K, Kira K, Saeki T, Tanaka I.
    J Pharmacol Exp Ther; 2004 Aug; 310(2):614-9. PubMed ID: 15039452
    [Abstract] [Full Text] [Related]

  • 8. Low insulin-like growth factor-II levels predict weight gain in normal weight subjects with type 2 diabetes.
    Heald AH, Kärvestedt L, Anderson SG, McLaughlin J, Knowles A, Wong L, Grill V, Cruickshank JK, White A, Gibson JM, Brismar K.
    Am J Med; 2006 Feb; 119(2):167.e9-15. PubMed ID: 16443426
    [Abstract] [Full Text] [Related]

  • 9. Treatment of type 2 diabetes with combined therapy: what are the pros and cons?
    Massi-Benedetti M, Orsini-Federici M.
    Diabetes Care; 2008 Feb; 31 Suppl 2():S131-5. PubMed ID: 18227473
    [Abstract] [Full Text] [Related]

  • 10. Sitagliptin: a novel drug for the treatment of type 2 diabetes.
    Choy M, Lam S.
    Cardiol Rev; 2007 Feb; 15(5):264-71. PubMed ID: 17700385
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
    Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P, Sitagliptin Study 035 Group.
    Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
    [Abstract] [Full Text] [Related]

  • 12. Metformin revisited: re-evaluation of its properties and role in the pharmacopoeia of modern antidiabetic agents.
    Goodarzi MO, Bryer-Ash M.
    Diabetes Obes Metab; 2005 Nov; 7(6):654-65. PubMed ID: 16219009
    [Abstract] [Full Text] [Related]

  • 13. Diabetes medications and body weight.
    Mitri J, Hamdy O.
    Expert Opin Drug Saf; 2009 Sep; 8(5):573-84. PubMed ID: 19538102
    [Abstract] [Full Text] [Related]

  • 14. Antidiabetic treatments and risk of hospitalisation with myocardial infarction: a nationwide case-control study.
    Horsdal HT, Søndergaard F, Johnsen SP, Rungby J.
    Pharmacoepidemiol Drug Saf; 2011 Apr; 20(4):331-7. PubMed ID: 21442682
    [Abstract] [Full Text] [Related]

  • 15. Why insulin sensitizers but not secretagogues should be retained when initiating insulin in type 2 diabetes.
    Raskin P.
    Diabetes Metab Res Rev; 2008 Apr; 24(1):3-13. PubMed ID: 17968971
    [Abstract] [Full Text] [Related]

  • 16. Metformin and body weight.
    Golay A.
    Int J Obes (Lond); 2008 Jan; 32(1):61-72. PubMed ID: 17653063
    [Abstract] [Full Text] [Related]

  • 17. Optimizing antidiabetic treatment options for patients with type 2 diabetes mellitus and cardiovascular comorbidities.
    Malesker MA.
    Pharmacotherapy; 2008 Feb; 28(2):193-206. PubMed ID: 18225965
    [Abstract] [Full Text] [Related]

  • 18. Hypoglycaemia in patients with type 2 diabetes treated with a combination of metformin and sulphonylurea therapy in France.
    Vexiau P, Mavros P, Krishnarajah G, Lyu R, Yin D.
    Diabetes Obes Metab; 2008 Jun; 10 Suppl 1():16-24. PubMed ID: 18435670
    [Abstract] [Full Text] [Related]

  • 19. [How to minimize weight gain associated with insulin treatment].
    Philippe J.
    Rev Med Suisse; 2010 Jun 09; 6(252):1199-200, 1202-4. PubMed ID: 20614755
    [Abstract] [Full Text] [Related]

  • 20. Treatment strategies for secondary sulfonylurea failure. Should we start insulin or add metformin? Is there a place for intermittent insulin therapy?
    Groop L, Widén E.
    Diabete Metab; 1991 May 09; 17(1 Pt 2):218-23. PubMed ID: 1936480
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.